Online Inquiry
Cat.#: ASSD-112
| Description | Propidium iodide (PI) is a widely used red-fluorescent intercalating agent that binds and labels nucleic acids. When bound to the nucleic acids, its fluorescence is enhanced 20- to 30-fold. Frequently used with Oxazole Yellow (YP1) when staining for apoptotic and necrotic cells as apoptotic cells remain impermeant to propidium iodide but permeable to Oxazole Yellow (YP1). |
| Synonyms | PI |
| Size | 1 mL |
| Applications | Flow cytometry, fluorescent microscopy and confocal laser scanning microscopy. Propidium iodide is membrane impermeant and is therefore frequently used to selectively identify dead cells and is commonly used in flow cytometry to evaluate cell viability. |
| Chemical Name | 2,7-Diamino-9-phenyl-10 (diethylaminopropyl)-phenanthridium iodide methiodide |
| Molecule Weight | 668.39 |
| Molecular formula | C27H34I2N4 |
| CAS Number | 25535-16-4 |
| PubChem identifier | 104981 |
| MDL Number | MFCD00011921 |
| Purity | >97% |
| Excitation | 535 nm |
| Emission | 617 nm |
| Storage | Store at 4° C |
| Shipping | Shipped at 4°C |
| Important | We strongly recommend storing this solution away from light. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-129 | Fluorescent 5-HT1A antagonist [NAN-190] (AC129) | 50 μg | inquiry |
| ASSD-169 | Calcium Ionophore A23187 (AC169) | 1mg, 5mg, 10 mg | inquiry |
| ASSD-197 | Sulforhodamine 101 acid chloride (AC197) | 10 mg, 25 mg | inquiry |
| ASSD-182 | 9-(2-Carboxy-2-cyanovinyl)julolidine (AC182) | 5 mg | inquiry |
| ASSD-137 | CCR2 covalent NAM (AC137) | 50 μg | inquiry |
| ASSD-147 | Rhodamine phalloidin-TRITC (AC147) | 300 tests, 100μg | inquiry |
| ASSD-144 | Oxazole Yellow Iodide (AC144) | 1 mg | inquiry |
| ASSD-124 | Fluorescent β2 antagonist [(S)-propranolol-green] (AC124) | 500 μg | inquiry |
| ASSD-140 | A2B covalent ligand (AC140) | 50 μg | inquiry |
| ASSD-121 | Fluorescent adenosine A3 antagonist [XAC] (AC121) | 500 μg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.